{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:15:51Z","timestamp":1783476951229,"version":"3.55.0"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"39","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,3,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Polycystic ovary syndrome (PCOS) is a frequent female reproductive endocrine disease.\nIt has been associated with a number of severe reproductive and metabolic abnormalities. However, there are still\nopen questions especially regarding the best long-term management.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods: <\/jats:title>\n<jats:p>We summarized the literature focused on the symptoms and negative long-term consequences of untreated\nPCOS and the existing options for the treatment. We reviewed the Pubmed and China National Knowledge\nInfrastructure databases and the relevant literature for the last 20 years. Included in this review also are new\nresults of own (published) research and own experience from treating daily more than 100 PCOS patients.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Obesity is one of the most common findings. It can cause abnormal ovulations which can lead to infertility.\nImportant long-term consequences can be adverse pregnancy outcomes. There is an agreement that the risk of\nendometrial cancer can be increased. Insulin resistance, important within the pathophysiology of PCOS, predisposes\npatients to metabolic dysfunction and increased risk of type 2 diabetes mellitus. Lifestyle modifications\nincluding dietary changes, exercise and weight loss are first-line interventions for many patients. Well known\ndrug treatments such as metformin, oral contraceptives, etc. should be selected according to the individual situation\nand patients' needs. Regarding newer methods in the long-term management of PCOS, we found that orlistat\nmay help to achieve weight loss and to improve lipid and glucose metabolism.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> In addition to pharmacological interventions, long-term standardized individualized management of\nPCOS patients is needed to achieve fertility and to reduce the risk of metabolic related diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190130104922","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:06:29Z","timestamp":1549019189000},"page":"4685-4692","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?"],"prefix":"10.2174","volume":"24","author":[{"given":"Xiangyan","family":"Ruan","sequence":"first","affiliation":[{"name":"Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred O.","family":"Mueck","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"Escobar-Morreale H.F.","year":"2018","unstructured":"Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.","journal-title":"Nat Rev Endocrinol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-14-0253","volume":"171","author":"Conway G.","year":"2014","unstructured":"Conway G, Dewailly D, Diamanti-Kandarakis E. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.","journal-title":"Eur J Endocrinol"},{"key":"ref=3","first-page":"19","volume":"81","author":"E.A-S. Pcwg","year":"2004","unstructured":"E.A-S. Pcwg, Revised R. 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.","journal-title":"Fertil Steril"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/09513590.2013.864273","volume":"30","author":"Tian X.","year":"2014","unstructured":"Tian X, Ruan X, Mueck AO. Anti-Mullerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China.","journal-title":"Gynecol Endocrinol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/09513590.2014.943719","volume":"30","author":"Tian X.","year":"2014","unstructured":"Tian X, Ruan X, Mueck AO. Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China.","journal-title":"Gynecol Endocrinol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/09513590.2017.1310838","volume":"33","author":"Jin J.","year":"2017","unstructured":"Jin J, Ruan X, Hua L. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters.","journal-title":"Gynecol Endocrinol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cen.12557","volume":"81","author":"Cassar S.","year":"2014","unstructured":"Cassar S, Teede HJ, Moran LJ. Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.","journal-title":"Clin Endocrinol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"Dumesic D.A.","year":"2015","unstructured":"Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.","journal-title":"Endocr Rev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","volume":"22","author":"Ehrmann D.A.","year":"1999","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.","journal-title":"Diabetes Care"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/humupd\/dms030","volume":"18","author":"Lim S.S.","year":"2012","unstructured":"Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2012.01053.x","volume":"14","author":"Lim S.S.","year":"2013","unstructured":"Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Obes Rev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1210\/jc.2016-2586","volume":"101","author":"Dumesic D.A.","year":"2016","unstructured":"Dumesic DA, Akopians AL, Madrigal VK. Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13048-015-0197-4","volume":"8","author":"Arpaci D.","year":"2015","unstructured":"Arpaci D, Gurkan Tocoglu A, Yilmaz S. The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome.","journal-title":"J Ovarian Res"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"E388","DOI":"10.1210\/jc.2012-3414","volume":"98","author":"Martinez-Garcia M.A.","year":"2013","unstructured":"Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS).","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"E576","DOI":"10.1210\/jc.2012-3438","volume":"98","author":"Montes-Nieto R.","year":"2013","unstructured":"Montes-Nieto R, Insenser M, Martinez-Garcia MA, Escobar-Morreale HF. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4103\/2230-8210.113759","volume":"17","author":"Ahmadi A.","year":"2013","unstructured":"Ahmadi A, Akbarzadeh M, Mohammadi F, Akbari M, Jafari B, Tolide-Ie HR. Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome.","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40279-014-0291-6","volume":"45","author":"Conte F.","year":"2015","unstructured":"Conte F, Banting L, Teede HJ, Stepto NK. Mental health and physical activity in women with polycystic ovary syndrome: a brief review.","journal-title":"Sports Med(Auckland, NZ)"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/humrep\/dew329","volume":"32","author":"Ollila M.M.","year":"2017","unstructured":"Ollila MM, West S, Keinanen-Kiukaaniemi S. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective population-based cohort study.","journal-title":"Hum Reprod"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11892-017-0956-2","volume":"17","author":"Torchen L.C.","year":"2017","unstructured":"Torchen LC. Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.","journal-title":"Curr Diab Rep"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1210\/jc.2012-1690","volume":"97","author":"Morgan C.L.","year":"2012","unstructured":"Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome matched, reference controls: a retrospective, observational study.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00404-017-4429-2","volume":"296","author":"Delitala A.P.","year":"2017","unstructured":"Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome.","journal-title":"Arch Gynecol Obstet"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12889-015-2147-x","volume":"15","author":"De Lucia Rolfe E.","year":"2015","unstructured":"De Lucia Rolfe E, Ong KK, Sleigh A, Dunger DB, Norris SA. Abdominal fat depots associated with insulin resistance and metabolic syndrome risk factors in black African young adults.","journal-title":"BMC Public Health"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11906-014-0500-6","volume":"16","author":"Luque-Ramirez M.","year":"2014","unstructured":"Luque-Ramirez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity.","journal-title":"Curr Hypertens Rep"},{"key":"ref=24","first-page":"128","volume":"120","author":"Setji T.L.","year":"2007","unstructured":"Setji TL, Brown AJ. Polycystic ovary syndrome: diagnosis and treatment.","journal-title":"Am J Obstet Gynecol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1210\/jc.2016-1659","volume":"101","author":"Legro R.S.","year":"2016","unstructured":"Legro RS, Dodson WC, Kunselman AR. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/09513590.2017.1292241","volume":"33","author":"Zhao Y.","year":"2017","unstructured":"Zhao Y, Ruan X, Mueck AO. Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study.","journal-title":"Gynecol Endocrinol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1210\/jc.2015-2778","volume":"100","author":"Legro R.S.","year":"2015","unstructured":"Legro RS, Dodson WC, Kris-Etherton PM. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/09513590.2015.1029447","volume":"31","author":"Wu H.","year":"2015","unstructured":"Wu H, Ruan X, Jin J, Mueck AO. Metabolic profile of Diane-35 Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.","journal-title":"Gynecol Endocrinol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1210\/jc.2016-1896","volume":"101","author":"Dokras A.","year":"2016","unstructured":"Dokras A, Sarwer DB, Allison KC. Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.fertnstert.2016.07.1069","volume":"106","author":"Riley J.K.","year":"2016","unstructured":"Riley JK, Jungheim ES. Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?","journal-title":"Fertil Steril"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12020-013-9971-5","volume":"44","author":"Panidis D.","year":"2013","unstructured":"Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.","journal-title":"Endocrine"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.fertnstert.2016.02.015","volume":"105","author":"Gaskins A.J.","year":"2016","unstructured":"Gaskins AJ, Chiu Y, Williams PL. Maternal whole grain intake and outcomes of fertilization.","journal-title":"Fertil Steril"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.fertnstert.2016.04.011","volume":"106","author":"McKinnon C.J.","year":"2016","unstructured":"McKinnon CJ, Hatch EE, Rothman KJ. Body mass index, physical activity and fecundability in a North American preconception cohort study.","journal-title":"Fertil Steril"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/oby.20777","volume":"22","author":"Unick J.L.","year":"2014","unstructured":"Unick JL, Hogan PE, Neiberg RH. Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention.","journal-title":"Obesity"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cen.13795","volume":"89","author":"Teede H.J.","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.","journal-title":"Clin Endocrinol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/09513590.2017.1407752","volume":"34","author":"Song J.","year":"2018","unstructured":"Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.","journal-title":"Gynecol Endocrinol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00404-018-4762-0","volume":"297","author":"Ruan X.","year":"2018","unstructured":"Ruan X, Song J, Gu M, Wang L, Wang H, Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.","journal-title":"Arch Gynecol Obstet"},{"key":"ref=38","first-page":"2","volume":"1","author":"Chen Z.","year":"2018","unstructured":"Chen Z, Tian Q, Qiao J. Guidelines for the diagnosis and treatment of polycystic ovary syndrome in China.","journal-title":"Chinese J Obst Gynecol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fendo.2014.00140","volume":"5","author":"Rasmussen C.B.","year":"2014","unstructured":"Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","volume":"7","author":"Zheng S.","year":"2017","unstructured":"Zheng S, Zhang Y, Long T. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women.","journal-title":"Obesity Med"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11695-015-1902-5","volume":"26","author":"Skubleny D.","year":"2016","unstructured":"Skubleny D, Switzer NJ, Gill RS. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis.","journal-title":"Obes Surg"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/humupd\/dmx012","volume":"23","author":"Escobar-Morreale H.F.","year":"2017","unstructured":"Escobar-Morreale HF, Santacruz E, Luque-Ramirez M, Botella Carretero JI. Prevalence of \u2018obesity-associated gonadal dysfunction\u2019 in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40738-016-0029-2","volume":"2","author":"Harris H.R.","year":"2016","unstructured":"Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.","journal-title":"Fertil Res Pract"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/humrep\/des042","volume":"27","author":"Haoula Z.","year":"2012","unstructured":"Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome.","journal-title":"Hum Reprod"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrendo.2014.102","volume":"10","author":"Jayasena C.N.","year":"2014","unstructured":"Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome.","journal-title":"Nat Rev Endocrinol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.286.19.2421","volume":"286","author":"Solomon C.G.","year":"2001","unstructured":"Solomon CG, Hu FB, Dunaif A. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.","journal-title":"JAMA"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/humupd\/dmu012","volume":"20","author":"Barry J.A.","year":"2014","unstructured":"Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mce.2012.10.029","volume":"373","author":"Bates G.W.","year":"2013","unstructured":"Bates GW, Legro RS. Longterm management of Polycystic Ovarian Syndrome (PCOS).","journal-title":"Mol Cell Endocrinol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1423-0127-21-2","volume":"21","author":"Li X.","year":"2014","unstructured":"Li X, Feng Y, Lin JF, Billig H, Shao R. Endometrial progesterone resistance and PCOS.","journal-title":"J Biomed Sci"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/jc.2013-1923","volume":"98","author":"Piltonen T.T.","year":"2013","unstructured":"Piltonen TT, Chen J, Erikson DW. Mesenchymal stem\/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2014.11.012","volume":"136","author":"Gottschau M.","year":"2015","unstructured":"Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study.","journal-title":"Gynecol Oncol"},{"key":"ref=52","first-page":"68","volume":"69","author":"Deligeoroglou E.","year":"2017","unstructured":"Deligeoroglou E, Karountzos V. Dysfunctional uterine bleeding as an early sign of polycystic ovary syndrome during adolescence: an update.","journal-title":"Minerva Ginecol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ygyno.2011.12.439","volume":"125","author":"Linkov F.","year":"2012","unstructured":"Linkov F, Maxwell GL, Felix AS. Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction.","journal-title":"Gynecol Oncol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2013.10.028","volume":"132","author":"Shafiee M.N.","year":"2014","unstructured":"Shafiee MN, Khan G, Ariffin R. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?","journal-title":"Gynecol Oncol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"8671762","DOI":"10.1155\/2016\/8671762","volume":"2016","author":"Lauretta R.","year":"2016","unstructured":"Lauretta R, Lanzolla G, Vici P, Mariani L, Moretti C, Appetecchia M. Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk.","journal-title":"Int J Endocrinol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","volume":"16","author":"","year":"2015","unstructured":". Collaborative Group on Epidemiological Studies on Endometrial CancerEndometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.","journal-title":"Lancet Oncol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13625187.2017.1317735","volume":"22","author":"Ruan X.","year":"2017","unstructured":"Ruan X, Kubba A, Aguilar A, Mueck AO. Use of cyproterone acetate\/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.maturitas.2015.06.030","volume":"82","author":"Ruan X.","year":"2015","unstructured":"Ruan X, Mueck AO. Oral contraception for women of middle age.","journal-title":"Maturitas"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.fertnstert.2004.01.041","volume":"82","author":"Carmina E.","year":"2004","unstructured":"Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.","journal-title":"Fertil Steril"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","volume":"91","author":"Lo J.C.","year":"2006","unstructured":"Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","volume":"16","author":"Moran L.J.","year":"2010","unstructured":"Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.fertnstert.2011.11.041","volume":"97","author":"Panidis D.","year":"2012","unstructured":"Panidis D, Tziomalos K, Macut D. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.","journal-title":"Fertil Steril"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1399-5448.2012.00902.x","volume":"14","author":"Flannery C.A.","year":"2013","unstructured":"Flannery CA, Rackow B, Cong X, Duran E, Selen DJ, Burgert TS. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI.","journal-title":"Pediatr Diabetes"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"Cassar S.","year":"2016","unstructured":"Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies.","journal-title":"Hum Reprod"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"Diamanti-Kandarakis E.","year":"2012","unstructured":"Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.","journal-title":"Endocr Rev"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/cen.12305","volume":"80","author":"Panidis D.","year":"2014","unstructured":"Panidis D, Tziomalos K, Papadakis E. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1210\/jc.2006-2794","volume":"92","author":"Vigorito C.","year":"2007","unstructured":"Vigorito C, Giallauria F, Palomba S. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1210\/jc.2010-0828","volume":"96","author":"Hutchison S.K.","year":"2011","unstructured":"Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cob.12258","volume":"8","author":"Benham J.L.","year":"2018","unstructured":"Benham JL, Yamamoto JM, Friedenreich CM, Rabi DM, Sigal RJ. Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Clin Obes"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2013-2385","volume":"98","author":"Domecq J.P.","year":"2013","unstructured":"Domecq JP, Prutsky G, Mullan RJ. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"Legro R.S.","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.metabol.2014.07.007","volume":"63","author":"Goss A.M.","year":"2014","unstructured":"Goss AM, Chandler-Laney PC, Ovalle F. Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS.","journal-title":"Metabolism"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14310\/horm.2002.1444","volume":"12","author":"Koiou E.","year":"2013","unstructured":"Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.","journal-title":"Hormones (Athens)"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/humupd\/dmn043","volume":"15","author":"Nieuwenhuis-Ruifrok A.E.","year":"2009","unstructured":"Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"","year":"2017","unstructured":". American Diabetes Association.8. Pharmacologic Approaches to Glycemic Treatment.","journal-title":"Diabetes Care"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2010.03917.x","volume":"74","author":"Li X.J.","year":"2011","unstructured":"Li XJ, Yu YX, Liu CQ. Metformin thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/dc17-S016","volume":"40","author":"","year":"2017","unstructured":". American Diabetes Association.13. Management of Diabetes in Pregnancy.","journal-title":"Diabetes Care"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"Elkind-Hirsch K.","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"Jensterle S.M.","year":"2014","unstructured":"Jensterle SM, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.","journal-title":"Eur J Endocrinol"},{"key":"ref=80","first-page":"373","volume":"16","author":"Lazaridou S.","year":"2017","unstructured":"Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome.","journal-title":"Hormones (Athens)"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-15-0275","volume":"173","author":"Vryonidou A.","year":"2015","unstructured":"Vryonidou A, Paschou SA, Muscogiuri G, Orio F, Goulis DG. Mechanisms in Endocrinology: Metabolic syndrome through the female life cycle.","journal-title":"Eur J Endocrinol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","volume":"111","author":"Legro R.S.","year":"2001","unstructured":"Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.","journal-title":"Am J Med"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2265.2001.01228.x","volume":"54","author":"Pirwany I.R.","year":"2001","unstructured":"Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2009-2444","volume":"95","author":"Phelan N.","year":"2010","unstructured":"Phelan N, O\u2019Connor A, Kyaw-Tun T. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000189809","volume":"18","author":"Ruan X.","year":"2009","unstructured":"Ruan X, Dai Y. Study on chronic low-grade inflammation and influential factors of polycystic ovary syndrome.","journal-title":"Med Princ Pract"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","volume":"95","author":"Wild R.A.","year":"2011","unstructured":"Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.","journal-title":"Fertil Steril"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF03345564","volume":"31","author":"Essah P.A.","year":"2008","unstructured":"Essah PA, Nestler JE, Carmina E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.","journal-title":"J Endocrinol Invest"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"Yusuf S.","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.","journal-title":"Lancet"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S34220","volume":"6","author":"Savva S.C.","year":"2013","unstructured":"Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/2230-8210.91195","volume":"16","author":"Anagnostis P.","year":"2012","unstructured":"Anagnostis P. Metabolic syndrome in the Mediterranean region: Current status.","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2017.09.016","volume":"86","author":"Anagnostis P.","year":"2018","unstructured":"Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences.","journal-title":"Metabolism"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humupd\/dmr001","volume":"17","author":"de Groot P.C.","year":"2011","unstructured":"de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis.","journal-title":"Hum Reprod Update"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"33715","DOI":"10.18632\/oncotarget.9553","volume":"7","author":"Zhao L.","year":"2016","unstructured":"Zhao L, Zhu Z, Lou H. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.","journal-title":"Oncotarget"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/ENDO:30:1:27","volume":"30","author":"Gorry A.","year":"2006","unstructured":"Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.","journal-title":"Endocrine"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"Sirmans S.M.","year":"2013","unstructured":"Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome.","journal-title":"Clin Epidemiol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000341824","volume":"40","author":"Panidis D.","year":"2013","unstructured":"Panidis D, Tziomalos K, Papadakis E, Katsikis I. Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.","journal-title":"Front Horm Res"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7827-11-56","volume":"11","author":"Qin J.Z.","year":"2013","unstructured":"Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis.","journal-title":"Reprod Biol Endocrinol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/09513590.2014.974535","volume":"31","author":"Katulski K.","year":"2015","unstructured":"Katulski K, Czyzyk A, Podfigurna-Stopa A, Genazzani AR, Meczekalski B. Pregnancy complications in polycystic ovary syndrome patients.","journal-title":"Gynecol Endocrinol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/1471-0528.12558","volume":"121","author":"Naver K.V.","year":"2014","unstructured":"Naver KV, Grinsted J, Larsen SO. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia.","journal-title":"BJOG"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.fertnstert.2017.12.023","volume":"109","author":"Li Y.","year":"2018","unstructured":"Li Y, Ruan X, Wang H. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment.","journal-title":"Fertil Steril"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/169465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/169465\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/169465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:54:36Z","timestamp":1608926076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/169465\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":100,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,3,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190130104922","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}